Skip to main content

Table 5 Faecal calprotectin levels in different stages of colorectal cancer

From: The role of faecal calprotectin in diagnosis and staging of colorectal neoplasia: a systematic review and meta-analysis

Author Year CRC total n Stage Comment
0/I II III IV
n (%) n (%) n (%) n (%)
FC (Median) FC (Median) FC (Median) FC (Median)
Gilbert 1996 14   5 (36.0) 2 (14.0) 7 (50.0) Stage had no effect on faecal calprotectin levels
Kristinsson 1998 119 25 (21.0) 33 (28.0) 36 (30.0) 25 (21.0) No significant difference
    50 mg/l 65 mg/l 34 mg/l 38 mg/l  
Kristinsson 2001 155 20 (13.0) 66 (43.0) 45 (29.0) 23 (15.0) No significant difference
    27 mg/l 49 mg/l 42 mg/l 48 mg/l  
Tibble 2001 62 10 (16.0) 24 (39.0) 14 (23.0) 14 (23.0) No significant difference (p > 0.2)
    62.5 mg/l 115 mg/l 62 mg/l 132 mg/l  
Karl 2008 85 (186) 23 (27.0) 27 (32.0) 12 (14.0) 23 (27.0) 85/186 CRC had stage specified
    179.2 μg/g 550.2 μg/g 542.5 μg/g 312.8 μg/g  
Kalimutho 2011 28 7 5 3   18 CRC either did not have FC or stage data
    4/7+ve FC 3/5+ve FC 3/3+ve FC   
Lehman 2014 80      Patients with T3/4 disease had significantly higher FC than T1/2 (p = 0.022)
  1. CRC colorectal cancer, FC faecal calprotectin